KyungDong Pharm home
Prescription Medicines

Bonbiron Inj.

Product Category
Osteoporosis treatment
Active Ingredients
Sodium ibandronate monohydrate
Appearance
It is an injection containing a colorless and transparent solution in a colorless and transparent glass prefilled syringe, and a disposable needle is attached.
Reimbursement Code
648103561
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 prefilled syringe
- Active ingredient: Sodium ibandronic acid monohydrate (in-house specification) ----------- 3.375mg (3mg as ibandronic acid)
- Additives: Sterile needle, acetic anhydride, sodium acetate hydrate, sodium chloride, water for injection

2. Effectiveness
Treatment of osteoporosis in postmenopausal women

3. Dosage and dosage
Inject 3 mg intravenously over 15 to 30 seconds once every three months.
Patients should take supplemental calcium and vitamin D.
If you forget to take the medication on a regular dosing day, inject it as soon as possible, and then take the medication regularly at 3-month intervals.
⦁ Patients with hepatic impairment: No dosage adjustment is necessary.
⦁ Patients with renal impairment
No dose adjustment is required for patients with mild or moderate renal impairment who have serum creatinine of 200 µmol/L (2.3 mg/dL) or less, or creatinine clearance of at least 30 mL/min. This medicine is not recommended for patients with serum creatinine above 200 µmol/L (2.3 mg/dL) or creatinine clearance below 30 mL/min because clinical experience in these patients is insufficient.
⦁ Elderly: No dose adjustment necessary.
⦁ Children and Adolescents: Efficacy and safety in children under 18 years of age have not been studied.

4. Precautions for use
1. Warning
This drug must be administered intravenously, and caution must be exercised as it may cause tissue damage when administered intraarterially or around a vein.

2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug or other ingredients of this drug
2) Patients with untreated hypocalcemia

3. Adverse reactions
1) The safety of ibandronate sodium single agent (oral) 2.5 mg administered once daily was evaluated in 1251 patients in four placebo-controlled clinical trials. ; 73% of these patients are part of a 3-year treatment clinical trial. In all trials, the overall safety profile of 2.5 mg sodium ibandronate (oral) administered once daily was similar to that of placebo. In therapeutic clinical trials, the overall proportion of patients who experienced adverse reactions, i.e., adverse reactions that were possibly or thought to be related to the test drug, were 19.8% and 17.9% in the ibandronate sodium single agent (oral) 2.5 mg and placebo groups, respectively.
2) In a 2-year clinical trial targeting postmenopausal osteoporosis patients, the overall safety profile of the group administered 3 mg of sodium ibandronate single agent (injection) intravenously once every three months and the group administered orally 2.5 mg of sodium ibandronate single agent (oral) once daily were similar. The overall proportion of patients who experienced adverse reactions after 1 and 2 years was 26.0% and 28.6% in the group administered 3 mg of sodium ibandronate single agent (injection) intravenously once every 3 months, and 20.4% and 22.6% in the group administered 2.5 mg sodium ibandronate single agent (oral) once daily. Most of the adverse reactions were mild to moderate and did not lead to discontinuation of treatment.
3) In clinical trials for the treatment of osteoporosis, the cases in which more than 1% of adverse reactions expected to be related to the test drug occurred after 1 and 2 years of treatment are listed in Tables 1 and 2. In this clinical trial, 3 mg of sodium ibandronate (injection) was administered intravenously once every three months, or 2.5 mg of sodium ibandronate (oral) was administered orally once a day. The table does not include adverse reactions that occurred equally or less frequently in the group that received 3mg sodium ibandronate single agent (injection) than in the oral administration group.
Additionally, Tables 1 and 2 also list adverse reactions in an anti-fracture clinical trial in which 2.5 mg of ibandronate sodium single agent (oral) was administered orally once a day for 3 years. The table shows adverse reactions that occurred at a higher frequency in the sodium ibandronate group compared to the placebo group in the anti-fracture clinical trial.

Table 1. Common adverse events (>1/100, ≤ 1/10) considered by investigators to be possibly related to the study drug after 1 year in the osteoporosis treatment clinical trial and in the anti-fracture clinical trial (3 years).
※ Refer to the manual

* Temporary influenza-like symptoms were generally reported in connection with the first dose in the group receiving 3 mg of sodium ibandronate (injection) as a single agent intravenously once every three months. Influenza-like illness is an acute phase reaction or symptom that includes joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, and bone pain. These symptoms are generally short-lived, mild-to-moderate in intensity, and resolve without medical intervention during treatment.

Table 2. Common adverse reactions (>1/100, ≤ 1/10) estimated by researchers to be possibly related to the test drug after 2 years in osteoporosis treatment clinical trials (cumulative data) and in anti-fracture clinical trials (3 years)
※ Refer to the manual

* Temporary influenza-like symptoms were generally reported in connection with the first dose in the group receiving 3 mg of sodium ibandronate (injection) as a single agent intravenously once every three months. Influenza-like illness is an acute phase reaction or symptom that includes joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, and bone pain. These symptoms are generally short-lived, mild-to-moderate in intensity, and resolve without medical intervention during treatment.

4) Adverse reactions that occurred in less than 1% of osteoporosis treatment clinical trials
※ Refer to the manual

5) There are reports that bisphosphonate drugs may be associated with eye inflammation such as uveitis or scleritis.
6) Overseas post-marketing survey
(1) Musculoskeletal and connective tissue abnormalities: In very rare cases, osteonecrosis of the jaw and external auditory canal has been reported in patients receiving ibandronate.
(2) Eye abnormalities: Eye inflammation such as uveitis, episcleritis, and scleritis have been reported when administering bisphosphonate drugs, including ibandronate. In some cases, these symptoms disappeared when bisphosphonate drugs were discontinued.
(3) Immune system abnormalities
- Anaphylactic reactions/shock, including fatal cases, have been reported in patients receiving ibandronate.
- Allergic reactions, including exacerbation of asthma, have been reported.
- Severe adverse skin events have been reported, including Steven Johnson syndrome, erythema multiforme, and bullous dermatitis.
(4) Complications related to wounds, poisoning, and procedures;
- Atypical subtrochanteric and diaphyseal femoral fractures have been reported when administering bisphosphonate drugs, including ibandronate.
- Atypical fractures of long bones (other than femur)
7) Domestic post-marketing survey
A 6-year post-marketing surveillance study conducted in Korea for re-examination included 628 patients. Adverse events, regardless of causality, were reported in 9.4% (59/628 patients; 102 events). Adverse drug reactions for which a causal relationship could not be excluded occurred in 6.2% (39/628 patients; 60 events). Reported reactions were myalgia in 12 patients (1.9%, 14 events); arthralgia in 6 (1.0%, 7 events); dyspepsia in 5 (0.8%, 6 events); influenza-like illness in 5 (0.8%, 5 events); musculoskeletal pain and headache, each in 4 (0.6%, 4 events); gastritis, nausea, fatigue, and dizziness, each in 2 (0.3%, 2 events); fever (0.2%, 3 events); and hypothyroidism, peripheral motor neuropathy, decreased hearing, dyspnea, skin exfoliation, multiple organ failure, and death, each in 1 patient (0.2%, 3 events), as reported in the source.
Serious adverse events were reported in one person each (0.2%, 1 case): fracture, multiple organ failure, and death. Among these, the causal relationship with the drug was not clear.
Unexpected adverse events were 3.2% (20/628 people) [31 cases], dizziness and fracture each at 0.5% (3/628 people) [3 cases], optic nerve atrophy, lower motor neuron lesion, tremor, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, Tinnitus, hearing loss, hypothyroidism, lipoma, eye hemorrhage, heart failure, urinary disorders, hematuria, and skin shedding were each reported at 0.2% (1/628 people) [1 case].
8) As a result of analyzing domestic voluntary adverse event reporting data (1989-June 2014), the following adverse events were reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
⦁ Nervous system: Decreased sensation
9) Acute renal failure has been reported during post-marketing use.

4. General precautions
1) This drug, like other intravenous bisphosphonate drugs, temporarily reduces serum calcium levels.
2) Hypocalcemia and bone and mineral metabolism disorders must be treated before administering this drug. It is important for all patients to consume adequate amounts of calcium and vitamin D. If your diet is insufficient, you should take calcium and/or vitamin D supplements.
3) Patients who have other diseases or are taking drugs that have a harmful effect on the kidneys must receive regular examination and treatment during the treatment period.
4) Osteonecrosis of the jaw
① Osteonecrosis of the jaw has been reported in patients receiving bisphosphonates. Most of the reported cases were cancer patients undergoing dental treatment, but such cases have also been reported in patients with osteoporosis or other diseases. Risk factors for osteonecrosis of the jaw include cancer diagnosis, concomitant therapy (e.g., chemotherapy including angiogenesis inhibitors, radiotherapy, corticosteroids), and concomitant diseases (e.g., anemia, coagulopathy, infection, and pre-existing dental disease). Most cases were reported in patients who took bisphosphonates intravenously, but some cases were also reported in patients who took bisphosphonates orally.
② Before administering bisphosphonates to patients with risk factors (cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene), oral examination, including appropriate preventive dental care, should be considered.
③ Excessive dental procedures should be avoided as much as possible during drug administration. In patients who develop osteonecrosis of the jaw while taking bisphosphonates, dental surgery may worsen the condition. There are no available data on whether discontinuation of bisphosphonates reduces the risk of osteonecrosis in patients requiring dental procedures. The benefits and risks of treatment are evaluated for each patient, and a patient treatment plan is established according to the clinical judgment of the relevant specialist.
5) Osteonecrosis of the external auditory canal has been reported in patients receiving bisphosphonates, including this drug. Risk factors include steroid use, chemotherapy, and/or local trauma and infection. The possibility of external auditory canal osteonecrosis should be considered in patients taking bisphosphonates who have chronic ear infections or symptoms such as ear discharge or pain.
6) Severe bone, joint and/or muscle pain has been reported in patients taking bisphosphonate drugs to prevent and treat osteoporosis. The time of symptom onset varied from 1 day to several months after drug administration. In most patients, symptoms were alleviated after stopping the drug, but symptoms recurred when the same drug or another bisphosphonate drug was taken again.
7) Atypical, low-energy, or low-trauma fractures of the femoral shaft have been reported in patients treated with bisphosphonates. These fractures can occur anywhere on the femoral stem, from the lesser trochanter to just above the supracondylar flare, and are essentially horizontal or short oblique in the absence of evidence of comminution. Because these fractures also occur in patients with osteoporosis who have not received bisphosphonate treatment, a causal relationship has not been established.
Atypical femur fractures most commonly occur after minimal or no trauma. This can occur both ways, and most patients report general pain, usually dull, aching thigh pain, in the affected area for weeks to months before a complete fracture occurs. A few reports mention the concurrent use of glucocorticoid treatment (e.g., prednisone) when fractures occur.
Any patient presenting with thigh or groin pain who has a history of exposure to bisphosphonates should be suspected of having an atypical fracture and evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be evaluated for signs and symptoms of fracture in the contralateral limb. Discontinuation of bisphosphonate therapy should be considered while awaiting individual benefit/risk assessment.
8) Atypical fractures of other bones, such as the ulna and tibia (other than the femur), have also been reported in patients receiving long-term treatment. Like atypical femur fractures, these fractures occur in patients with minimal or no trauma, and in some patients pain occurs as a prodromal symptom before a complete fracture. Ulna fractures may be related to repetitive stress loading associated with long-term use of a walker.
9) When administering this drug intravenously, appropriate medical measures and monitoring must be provided immediately. If anaphylaxis or other severe hypersensitivity/allergic reaction occurs, immediately stop injecting this medication and initiate appropriate treatment.

5. Interaction
1) When administered in combination with melphalan/prednisolone to patients with multiple myeloma, no interaction was observed.
2) In a pharmacokinetic study on postmenopausal women, there was no interaction with tamoxifen or hormone replacement therapy (estrogens).
3) This drug is not converted in the liver, does not inhibit the major liver cytochrome P450 isoenzyme in humans, and does not induce the liver cytochrome P450 system in rats, so there is no concern about drug interactions due to drug metabolism. Additionally, plasma protein binding was approximately 85%-87% (confirmed at therapeutic drug concentration through in vitro testing). Additionally, this drug is excreted only through renal secretion and does not undergo biotransformation. The secretory pathway does not involve the acid or base transport systems involved in the excretion of other drugs already known.

6. Administration to pregnant and lactating women
Do not use this drug because there is no experience using this drug and the potential risk to humans is unknown.
1) Pregnant women: As a result of animal testing on rats, reproductive toxicity was observed.
2) Nursing mothers: Animal tests on rats showed that when administered intravenously, a small amount of this drug passed into breast milk. It is not known whether this drug passes into human breast milk.

7. Administration to elderly people
No dose adjustment is necessary.

8. Administration to children
Efficacy and safety in children under 18 years of age have not been studied.

9. Effect on clinical test values
In a clinical trial in which 2.5 mg of sodium ibandronate (oral) was administered once a day for 3 years, there was no difference in clinical laboratory abnormalities indicating liver or kidney failure, hematological damage, hypocalcemia, or hypophosphatemia compared to placebo. Similarly, in a clinical trial in which 3 mg of ibandronate sodium single agent (injection) was administered intravenously once every three months for one year, no differences were observed between groups.

10. Treatment in case of overdose
1) There has been no experience of acute poisoning with this drug so far.
2) Because both kidneys and liver are known to be target organs of toxicity in high-dose preclinical trials, liver and renal functions should be monitored.
3) In case of overdose, very careful monitoring is required. If clinically significant hypocalcemia, hypophosphatemia, or hypomagnesemia occurs due to overdose, it should be treated with intravenous injection of calcium gluconate, sodium phosphate or potassium phosphate, and magnesium sulfate, respectively. Dialysis is not beneficial more than 2 hours after overdose.

11. Effects on driving and operating machines
The effect of this drug on driving and operating machinery has not been studied.

12. Application and handling precautions
1) This drug should not be mixed with calcium-containing solutions or other intravenous drugs.
2) Must be administered intravenously.
3) When administering this drug through an existing intravenous infusion line, the infusion solution should be physiological saline or 50 mg/mL (5%) glucose solution. This also applies to solutions used to wash butterfly and other devices.
4) Store out of reach of children.
5) Disposal of injection needles
① Do not reuse injection needles and syringes.
② Used needles and syringes must be placed in a puncture-proof disposal container and disposed of separately from household waste.


5. How to save
Sealed container, stored at room temperature (1~30℃)

6. Packaging unit
3mL/prefilled syringe

7. Period of use
24 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Bonbiron Inj.Precautions for use2025.09.30PDFPrecautions for using Bonvironju.pdf
4Bonbiron Inj.Bonvironju (precautions for use)2019.08.20PDFPrecautions for using Bonvironju.pdf
3Bonbiron Inj.Bonvironju (precautions for use)2017.06.16HWPPrecautions for using Bonvironju.hwp
2Bonbiron Inj.Bonvironju (precautions for use)2015.10.29HWPIvandronic acid.hwp
1Bonbiron Inj.Bonvironju (precautions for use)2015.08.20HWPUnification adjustment plan for sodium ibandronate monohydrate single-dose injection.h